Capricor Cuts 10% of Staff Amid FDA Review
The San Diego biotech reduced its workforce in the third quarter as it awaits a decision on its deramiocel therapy.
Updated on Nov. 11, 2026 in Industry

Capricor Therapeutics laid off 10% of its workforce during the third quarter, a move the company said was made to reduce operating expenses and align resources with its priorities. The cuts come as the company awaits a delayed FDA decision on its deramiocel application.
Why it matters
The reduction reflects the financial pressure facing development-stage biotechs while regulatory outcomes remain pending. How the FDA rules on deramiocel will shape the company's next steps and whether it needs further restructuring.
Capricor reported $198.5 million in cash at the end of September 2025 after cutting 10% of a 231-person workforce. The company has not said how many roles were eliminated or whether further reductions are planned.
The players
Capricor Therapeutics
A San Diego-based biotechnology company developing deramiocel, a cell-based therapy for muscular dystrophy.
U.S. Food and Drug Administration
The federal agency responsible for reviewing and approving drug applications, including Capricor's deramiocel.
The details
Capricor disclosed the layoffs in its third-quarter earnings results. The company also submitted two-year open-label extension data from a phase 3 study as part of its deramiocel application, after the FDA rejected its first application, based on phase 2 data, last year.
Timeline
Last year: FDA rejected Capricor's first deramiocel application.
July: An FDA advisory committee voted against Capricor's second deramiocel application.
Third quarter: Capricor completed its workforce reduction.
Later this month: The FDA is expected to issue its deramiocel decision, pushed back three months from an earlier August target.
Market Landscape
Capricor's cuts follow a rejected first application and a negative advisory vote, illustrating how regulatory setbacks force small San Diego biotechs to shrink operations while awaiting approval decisions. The company's trajectory will indicate whether such restructuring becomes a common pattern across development-stage peers in the region.
For San Diego residents tracking the local biotech job market, the cuts signal tighter hiring conditions at companies still dependent on pending federal approvals. Investors and employees should watch the FDA's ruling, which will determine whether further workforce changes follow.
The takeaway
Regulatory timelines can stretch well beyond original targets, and biotech companies often respond by trimming staff before a decision arrives. Tracking cash runway alongside FDA milestones gives a clearer picture of a company's stability.
What happens next
Capricor's deramiocel FDA decision is expected later this month, and the outcome will determine the company's near-term financing and staffing plans.
Further reading
For more on the local life sciences sector, explore Healthcare coverage tied to San Diego.






